Show simple item record

dc.contributor.authorAkeju, Oluwaseun
dc.contributor.authorHobbs, Lauren E.
dc.contributor.authorGao, Lei
dc.contributor.authorBurns, Sara M.
dc.contributor.authorPavone, Kara J.
dc.contributor.authorPlummer, George S.
dc.contributor.authorWalsh, Elisa C.
dc.contributor.authorHoule, Tim T.
dc.contributor.authorKim, Seong-Eun
dc.contributor.authorBianchi, Matt T.
dc.contributor.authorEllenbogen, Jeffrey M.
dc.contributor.authorBrown, Emery Neal
dc.date.accessioned2020-07-29T23:55:12Z
dc.date.available2020-07-29T23:55:12Z
dc.date.issued2017-10
dc.identifier.issn1388-2457
dc.identifier.urihttps://hdl.handle.net/1721.1/126436
dc.description.abstractObjectives Sleep, which comprises of rapid eye movement (REM) and non-REM stages 1–3 (N1–N3), is a natural occurring state of decreased arousal that is crucial for normal cardiovascular, immune and cognitive function. The principal sedative drugs produce electroencephalogram beta oscillations, which have been associated with neurocognitive dysfunction. Pharmacological induction of altered arousal states that neurophysiologically approximate natural sleep, termed biomimetic sleep, may eliminate drug-induced neurocognitive dysfunction. Methods We performed a prospective, single-site, three-arm, randomized-controlled, crossover polysomnography pilot study (n = 10) comparing natural, intravenous dexmedetomidine- (1-μg/kg over 10 min [n = 7] or 0.5-μg/kg over 10 min [n = 3]), and zolpidem-induced sleep in healthy volunteers. Sleep quality and psychomotor performance were assessed with polysomnography and the psychomotor vigilance test, respectively. Sleep quality questionnaires were also administered. Results We found that dexmedetomidine promoted N3 sleep in a dose dependent manner, and did not impair performance on the psychomotor vigilance test. In contrast, zolpidem extended release was associated with decreased theta (∼5–8 Hz; N2 and N3) and increased beta oscillations (∼13–25 Hz; N2 and REM). Zolpidem extended release was also associated with increased lapses on the psychomotor vigilance test. No serious adverse events occurred. Conclusions Pharmacological induction of biomimetic N3 sleep with psychomotor sparing benefits is feasible. Significance These results suggest that α2a adrenergic agonists may be developed as a new class of sleep enhancing medications with neurocognitive sparing benefits.en_US
dc.description.sponsorshipNational Institutes of Health (Grant TR01 GM104948)en_US
dc.language.isoen
dc.publisherElsevier BVen_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.clinph.2017.10.005en_US
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs Licenseen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en_US
dc.sourcePMCen_US
dc.titleDexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot studyen_US
dc.typeArticleen_US
dc.identifier.citationAkeju, Oluwaseun et al. "Dexmedetomidine promotes biomimetic non-rapid eye movement stage 3 sleep in humans: A pilot study." Clinical Neurophysiology 129, 1 (January 2018): 69-78 © 2017 International Federation of Clinical Neurophysiologyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Brain and Cognitive Sciencesen_US
dc.relation.journalClinical Neurophysiologyen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2019-09-30T15:26:58Z
dspace.date.submission2019-09-30T15:27:01Z
mit.journal.volume129en_US
mit.journal.issue1en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record